Results 1 to 10 of about 182,500 (270)
Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1.
Irfan Cicin +15 more
doaj +1 more source
Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients
Background: Pembrolizumab is a standard first-line treatment for metastatic non–small cell lung cancer (NSCLC). Although approved dosing regimens achieve near-maximal PD-1 receptor occupancy in clinical trials, variability in pembrolizumab exposure in ...
Cristina Martínez-Toledo +27 more
doaj +1 more source
Background Although pembrolizumab has been shown to be effective, its high price has prevented it from being widely used. Especially in the real world, the application situation is still uncertain.
Ning Wan +15 more
doaj +1 more source
Introduction Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune‐related adverse event of pembrolizumab therapy in a patient with ...
Naoki Inoue +5 more
doaj +1 more source
Background Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC).
Jing Nie +6 more
doaj +1 more source
Some of the next articles are maybe not open access.

